Cargando…

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

The recent identification and rise to dominance of the P.1 and B.1.351 SARS-CoV-2 variants have brought international concern because they may confer fitness advantages. The same three positions in the receptor-binding domain (RBD) are affected in both variants, but where the 417 substitution differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayarri-Olmos, Rafael, Jarlhelt, Ida, Johnsen, Laust Bruun, Hansen, Cecilie Bo, Helgstrand, Charlotte, Rose Bjelke, Jais, Matthiesen, Finn, Nielsen, Susanne Dam, Iversen, Kasper Karmark, Ostrowski, Sisse Rye, Bundgaard, Henning, Frikke-Schmidt, Ruth, Garred, Peter, Skjoedt, Mikkel-Ole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529273/ https://www.ncbi.nlm.nih.gov/pubmed/34691078 http://dx.doi.org/10.3389/fimmu.2021.757197

Ejemplares similares

The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Reply to Lassaunière: On the functional characterization of the Y453F RBD variant found in cluster 5 SARS-CoV-2
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19
por: Götz, Maximilian Peter, et al.
Publicado: (2022)

Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
por: Pérez-Alós, Laura, et al.
Publicado: (2023)

SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
por: Jarlhelt, Ida, et al.
Publicado: (2021)

Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
por: Pérez-Alós, Laura, et al.
Publicado: (2022)

Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities
por: Hertz, Cecilie E., et al.
Publicado: (2018)

Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
por: Jarlhelt, Ida, et al.
Publicado: (2023)

Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2018)

COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant
por: Saha, Senjuti, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
por: Kim, Yeong Jun, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
por: Madsen, Johannes Roth, et al.
Publicado: (2023)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
por: Feder, Kenneth A., et al.
Publicado: (2021)

Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong
por: Tsang, Alan K.L., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Correction: The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients
por: Ruscheweyh, Ruth, et al.
Publicado: (2022)

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
por: Dayan, Gustavo H., et al.
Publicado: (2023)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Effects of B.1.1.7 and B.1.351 on COVID-19 Dynamics: A Campus Reopening Study
por: Linka, Kevin, et al.
Publicado: (2021)

Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
por: Harboe, Zitta Barrella, et al.
Publicado: (2022)

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
por: Heftdal, Line Dam, et al.
Publicado: (2023)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021)

Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021
por: Calba, Clémentine, et al.
Publicado: (2021)

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
por: Du, Shuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v91k07hjlb1f2rmc9j21v295u0